Insulet Corporation
Insulet Appoints New Board Members and Announces Retirements
Summary
Insulet Corporation announced on January 18, 2024, the appointment of Flavia Pease and Tim Stonesifer to its Board of Directors, effective January 18, 2024. Pease and Stonesifer will stand for election by stockholders at the Company's 2024 and 2026 Annual Meetings, respectively. Simultaneously, the Company announced the retirements of Shacey Petrovic and Corinne Nevinny from the Board at the 2024 Annual Meeting, marking the end of their distinguished service. These changes are set to enhance the Board's expertise and leadership.
Profitelligence Alerts
Get alerts for PODD
Be first to know when Insulet Corporation files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Insulet Corporation
Insulet Corporation is a prominent healthcare company specializing in medical devices, with a key focus on diabetes management. Its flagship product, the Omnipod Insulin Management System, is an innovative, tubeless insulin pump that offers users freedom and flexibility, addressing the lifelong needs of individuals with diabetes. The system is acclaimed for its discreet, water-resistant pods, which deliver continuous insulin delivery without the constraints of traditional insulin pumps. Insulet Corporation plays a crucial role in the medical technology industry by enhancing patient experiences and outcomes. Headquartered in Acton, Massachusetts, Insulet Corporation continues to pioneer advancements in insulin delivery solutions, directly impacting healthcare providers and improving the quality of life for diabetes patients globally. Its market significance is underscored by its commitment to innovation and accessibility, bridging the gap between technology and patient-centric care in the rapidly evolving healthcare sector.
Official SEC Documents
Advertisement